Enliven Therapeutics closes upsized public offering, raises USD 460 million gross

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

ELVN

0.00
  • Enliven Therapeutics closed an upsized underwritten public offering of 10,533,334 common shares priced at USD 37.5 each.
  • Deal included full exercise of the underwriters’ option for 1,600,000 additional common shares.
  • Issued pre-funded warrants for 1,733,333 shares at USD 37.499 each, with a USD 0.001 per share exercise price.
  • Gross proceeds totaled about USD 460 million before underwriting discounts, commissions, and offering expenses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606151640PR_NEWS_USPR_____LA84149) on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.